PRMT5 and neoplasm: In the same study, the PRMT5 inhibitor C220 reduced the transcription and altered the splicing pattern of selected DDR genes and enhanced tumor cell sensitivity to the DNA damaging chemotherapeutic agents cisplatin, olaparib and 5-FU.